Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Vaccinex, Inc. Common Stock (VCNX)

Pharmaceutical Preparations

https://www.vaccinex.com

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.

1895 MOUNT HOPE AVE
ROCHESTER, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/09/2018

Market Cap

8,461,929

Shares Outstanding

12,490,000

Weighted SO

12,494,275

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

TARA --.--%

MNPR --.--%

MIRO --.--%

SRZN --.--%

FWBI --.--%

SLRX --.--%

SABS --.--%

GOVX --.--%

Beta

0.9160

Last Div

0.0000

Range

4.21-52.5

Chg

-0.0222

Avg Vol

84530

Mkt Cap

8461929

Exch

NASDAQ

Country

US

Phone

585 271 2700

DCF Diff

6.9226

DCF

-0.0325

Div Yield

0.0000

P/S

-282.0643

EV Multiple

-0.3868

P/FV

-3.1082

Div Yield %

0.0000

P/E

-0.5013

PEG

-0.0970

Payout

0.0000

Current Ratio

0.4210

Quick Ratio

0.4210

Cash Ratio

0.0445

DSO

-12714.1545

DIO

0.0033

Op Cycle

-12714.1512

DPO

10810.0000

CCC

-23524.1512

Gross Margin

4.6500

Op Margin

720.6000

Pretax Margin

591.9000

Net Margin

591.9000

Eff Tax Rate

0.3248

ROA

-7.5019

ROE

11.1172

ROCE

7.5482

NI/EBT

1.0000

EBT/EBIT

0.8214

EBIT/Rev

720.6000

Debt Ratio

0.0515

D/E

-0.0426

LT Debt/Cap

0.0000

Total Debt/Cap

-0.0445

Int Coverage

-52.5985

CF/Debt

-92.7787

Equity Multi

-0.8265

Rec Turnover

-0.0287

Pay Turnover

0.0338

Inv Turnover

109500.0000

FA Turnover

-0.1818

Asset Turnover

-0.0127

OCF/Share

-6.2277

FCF/Share

-6.2376

Cash/Share

0.1282

OCF/Sales

377.3000

FCF/OCF

1.0016

CF Coverage

-92.7787

ST Coverage

-92.7787

CapEx Coverage

-628.8333

Div&CapEx Cov

-628.8333

P/BV

-3.1082

P/B

-3.1082

P/S

-282.0643

P/E

-0.5013

P/FCF

-0.7464

P/OCF

-0.7865

P/CF

-0.7865

PEG

-0.0970

P/S

-282.0643

EV Multiple

-0.3868

P/FV

-3.1082

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Oct 26, 09:30 Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Revenue Product Segmentation